Kimberly A. Aron

Array ( [id] => 19709267 [patent_doc_number] => 20250019409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-16 [patent_title] => POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/283523 [patent_app_country] => US [patent_app_date] => 2022-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51167 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -94 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18283523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17684889 [patent_doc_number] => 20220192181 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => CRYOPRESERVATION OF VIABLE HUMAN SKIN SUBSTITUTES [patent_app_type] => utility [patent_app_number] => 17/694245 [patent_app_country] => US [patent_app_date] => 2022-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11528 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17694245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20401275 [patent_doc_number] => 12491235 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Methods and compositions for treating metabolic imbalance in neurodegenerative disease [patent_app_type] => utility [patent_app_number] => 17/574847 [patent_app_country] => US [patent_app_date] => 2022-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 330 [patent_figures_cnt] => 81 [patent_no_of_words] => 17126 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17574847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20593880 [patent_doc_number] => 12577584 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-17 [patent_title] => Non-HLA matched humanized NSG mouse model with patient-derived xenograft [patent_app_type] => utility [patent_app_number] => 17/569660 [patent_app_country] => US [patent_app_date] => 2022-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 54 [patent_no_of_words] => 10900 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17569660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17563490 [patent_doc_number] => 20220127639 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT [patent_app_type] => utility [patent_app_number] => 17/569788 [patent_app_country] => US [patent_app_date] => 2022-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14333 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17569788 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20480400 [patent_doc_number] => 12528871 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-20 [patent_title] => Universal immune cells for cancer immunotherapy [patent_app_type] => utility [patent_app_number] => 17/647122 [patent_app_country] => US [patent_app_date] => 2022-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 14088 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17647122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18526352 [patent_doc_number] => 11713337 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-01 [patent_title] => Peptide, compositions and method for delivery of agents into cells and tissues [patent_app_type] => utility [patent_app_number] => 17/646496 [patent_app_country] => US [patent_app_date] => 2021-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 24 [patent_no_of_words] => 21775 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17646496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17701987 [patent_doc_number] => 20220201993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => MICE THAT MAKE HEAVY CHAIN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/550927 [patent_app_country] => US [patent_app_date] => 2021-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17816 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17550927 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17732496 [patent_doc_number] => 20220217955 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => Non-Human Animals Expressing pH-Sensitive Immunoglobulin Sequences [patent_app_type] => utility [patent_app_number] => 17/545099 [patent_app_country] => US [patent_app_date] => 2021-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 84303 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17545099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20577355 [patent_doc_number] => 12569592 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-10 [patent_title] => Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof [patent_app_type] => utility [patent_app_number] => 17/532893 [patent_app_country] => US [patent_app_date] => 2021-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 36662 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17532893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399896 [patent_doc_number] => 20220041986 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => Truncated Epiderimal Growth Factor Receptor (EGFRt) for Transduced T Cell Selection [patent_app_type] => utility [patent_app_number] => 17/507996 [patent_app_country] => US [patent_app_date] => 2021-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8422 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17507996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17383965 [patent_doc_number] => 20220031817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => ENHANCED THERAPEUTIC USAGE OF A PURINE NUCLEOSIDE PHOSPHORYLASE OR NUCELOSIDE HYDROLASE PRODRUG [patent_app_type] => utility [patent_app_number] => 17/502101 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9283 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17502101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17426855 [patent_doc_number] => 20220054563 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES [patent_app_type] => utility [patent_app_number] => 17/448549 [patent_app_country] => US [patent_app_date] => 2021-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17448549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17519285 [patent_doc_number] => 20220105133 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY [patent_app_type] => utility [patent_app_number] => 17/481404 [patent_app_country] => US [patent_app_date] => 2021-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48740 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17481404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20548942 [patent_doc_number] => 12559724 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-24 [patent_title] => Genetically modified mesenchymal stem cell expressing Klotho [patent_app_type] => utility [patent_app_number] => 17/447975 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16268 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17447975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441933 [patent_doc_number] => 20220062438 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => CODON OPTIMIZED REP1 GENES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/463262 [patent_app_country] => US [patent_app_date] => 2021-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16359 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17463262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17293377 [patent_doc_number] => 20210389216 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => FIXATION OF A BIOLOGICAL MATERIAL [patent_app_type] => utility [patent_app_number] => 17/411667 [patent_app_country] => US [patent_app_date] => 2021-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15175 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17275739 [patent_doc_number] => 20210381937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => FIXATION OF A BIOLOGICAL MATERIAL [patent_app_type] => utility [patent_app_number] => 17/411675 [patent_app_country] => US [patent_app_date] => 2021-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15185 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17411675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299944 [patent_doc_number] => 20210395783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => PRIMARY CELL GENE EDITING [patent_app_type] => utility [patent_app_number] => 17/400974 [patent_app_country] => US [patent_app_date] => 2021-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43319 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17400974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19840156 [patent_doc_number] => 12252525 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Chimeric T cell receptors, nucleic acids, and methods of making and using the same [patent_app_type] => utility [patent_app_number] => 17/387347 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 68 [patent_figures_cnt] => 51 [patent_no_of_words] => 10397 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387347 [rel_patent_id] =>[rel_patent_doc_number] =>)